Erik Duijvelaar

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.

Empagliflozin Ameliorates Experimental Pulmonary Vascular Remodeling, but May Not Benefit Patients With Pulmonary Arterial Hypertension.

Journal: Journal of the American Heart Association
Published: July 25, 2026

Correction: Machine learning reveals limited predictive value of clinical factors for asthma exacerbations.

Correction: Machine learning reveals limited predictive value of clinical factors for asthma exacerbations.

Journal: Scientific reports
Published: December 02, 2025

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.

Journal: American journal of respiratory and critical care medicine
Published: August 20, 2025

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury.

Journal: American journal of respiratory and critical care medicine
Published: August 20, 2025

Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome.

Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 acute respiratory distress syndrome.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: June 20, 2025

Machine learning reveals limited predictive value of clinical factors for asthma exacerbations.

Machine learning reveals limited predictive value of clinical factors for asthma exacerbations.

Journal: Scientific reports
Published: May 14, 2025

Deep phenotyping of pulmonary edema and pulmonary vascular permeability in COVID-19 ARDS.

Deep phenotyping of pulmonary edema and pulmonary vascular permeability in COVID-19 ARDS.

Journal: American journal of physiology. Lung cellular and molecular physiology
Published: October 22, 2024

Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.

Imatinib treatment improves hyperglycaemic dysregulation in severe COVID-19: a secondary analysis of blood biomarkers in a randomised controlled trial.

Journal: Critical care (London, England)
Published: December 08, 2023

Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.

Longitudinal plasma proteomics reveals biomarkers of alveolar-capillary barrier disruption in critically ill COVID-19 patients.

Journal: Nature communications
Published: April 28, 2023

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.

Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial.

Journal: Critical care (London, England)
Published: April 04, 2023

Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.

Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: September 27, 2022

Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.

Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial.

Journal: Journal of cardiovascular pharmacology
Published: April 28, 2022
Showing 1-12 of 17

Last Updated: 09/26/2026